On May 17, AstraZeneca announced that benralizumab achieved statistically significant reductions in annual exacerbation rates compared to placebo in patients with severe asthma with eosinophilic inflammation in the Phase III SIROCCO and CALIMA studies. Patients in SIROCCO (n=1,206) and CALIMA (n=1,305) were uncontrolled on inhaled corticosteroids and/or long-acting beta agonist (LABA) therapy, with or without oral corticosteroids or other therapies.
AstraZeneca Hopes To Differentiate Benralizumab On Efficacy, Dosing Convenience
AstraZeneca PLC is keeping a tight lid on Phase III data for its biologic for severe asthma, benralizumab, other than to say it met its primary endpoint in a pair of pivotal trials – but the pharma hopes to offer differentiating efficacy from GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. biologics already approved for this indication when it unveils the full datasets at a scientific meeting later this year.
More from Clinical Trials
• By
Aldeyra’s dry eye candidate reproxalap received a second FDA complete response letter, but the firm expressed confidence about refiling quickly based on two ongoing studies.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.